EHRA-PATHS: Clinical and Health Economic Evaluation of New Care Pathways

Recruiting · NCT05773768 · Interventional (participants receive a specific treatment) · Lead sponsor: University Medical Center Groningen

View the official record on ClinicalTrials.gov →

Atrial Fibrillation

Interventions studied

EHRA-PATHS software tool

What this trial is about

In elderly atrial fibrillation (AF) patients, AF is usually a manifestation of risk factors and comorbidities not only limited to cardiovascular diseases. Especially in elderly often more than two comorbidities are present. The presence of comorbidities also affects outcomes in AF patients. Current healthcare systems are single-disease focused, which increases the risk of underdiagnosing, replicating diagnostic tests and adverse drug-drug interactions, placing a high burden on healthcare costs. Healthcare systems and hospitals are in need of new care pathways to address the complexity of multimorbid AF patients and to reduce costs. The EHRA-PATHS consortium set out to address this need for change in management for multimorbid, elderly AF patients in Europe through the development of new care pathways. The aim of this study is to evaluate the current management of risk factors and comorbidities, and subsequently implement the newly developed care pathways and evaluate if these pathways lead to better management of risk factors and comorbidities in multimorbid, elderly AF patients, compared to current standard care.

Who can take part

Age range

65 Years and older

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not applicable (e.g. observational or device study)

Study type

Interventional (participants receive a specific treatment)

Inclusion criteria

Newly diagnosed atrial fibrillation (paroxysmal, persistent or permanent)
≥65 years of age
Willing and able to participate and to attend the scheduled follow-up visits.

Exclusion criteria

Atrial fibrillation episode was due to a trigger (i.e. postoperative, infection, hyperthyroidism etc.)
Life expectancy of less than 1 year
Participation in another clinical study (registry studies not included)
Severe cognitive impairment / dementia (defined based on MMSE and CDR scoring systems)

Where it is running

1 location listed.

University Medical Center Groningen - Groningen, Netherlands

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →